ERBB2 and breast cancer: Moreover, DHA may be promising in treating aggressive breast cancers, having been shown to act synergistically with both Doxorubicin, for triple-negative breast cancers, and Trastuzumab, for HER2+ breast cancers, while displaying the ability to bind to translationally controlled tumour proteins (TCTP) which tend to be overexpressed in high grade breast cancers and tumours conferring resistance to treatment using Trastuzumab.